QC Microbiology Analyst I: Alexion Pharmaceuticals,Inc.

Responsiblities:

• Follow written procedures for the following tests, as trained and qualified: environmental air and surface sampling, water sampling and water testing for conductivity, TOC, bioburden, endotoxin and media qualification testing
• Order, stock, receive, label, log and inventory lab supplies.
• Receive and prepare test samples for QC and contract lab testing.
• Perform support work for QC laboratory including lab cleaning, equipment cleaning and maintenance, preparation of reagents and solutions.
• Perform lab administrative functions as assigned.
• Perform all job functions in compliance with cGMPs and maintain accurate and legible laboratory records
• Write and revise basic laboratory SOPs as assigned.
• Perform in-process and product release and stability testing, as trained and qualified for: bioburden and endotoxin
• Ensure training is current for all job functions performed. Attend all required company training.
• Assist in other laboratory functions and testing as trained and assigned.

• The individual in this position is expected to have a basic understanding of the laboratory environment and be familiar with basic laboratory equipment / instrumentation: pH meters, balances, BSCs, incubators, etc.
• This position requires the individual to understand and follow written SOPs, record all work legibly and in real time; close attention to detail is necessary.
• The person in this position will receive direct supervision on all non-routine activities. It is expected that routine activities will become unsupervised as training and competency develops.
• A basic understanding of the concepts and systems applied to the tests and cGMP operations is expected.

Requirements

• AS / BS in Microbiology or other biological science
• 0 – 2 years experience

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Employing more than 500 people worldwide, Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders. Soliris^(R) (eculizumab) is Alexion's first marketed product for patients with paroxysmal noctural hemoglobinuria (PNH) a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is approved in the U.S. and Europe in 2007, and Canada and Australia in 2009. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development.

Alexion offers a highly competitive package of base and incentive compensation, group healthcare coverage, tuition reimbursement, relocation assistance, and a 401(K) plan.

Alexion is an Equal Opportunity/Affirmative Action Employer.